Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.75 |
| ▸ | RAB9A | P51151 | 6/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.75 |
| ▸ | NPC1 | O15118 | 5/20 | 0.75 |
| ▸ | MEN1 | O00255 | 4/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.75 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.61 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 2/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.60 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4117508 | 0.87 | MAPT (0.70) | MAPTRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL4104375 | 0.86 | RAB9A (0.71) | MAPTRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL4105155 | 0.86 | MAPT (1.00) | MAPTRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL4104918 | 0.86 | MAPT (0.68) | MAPTRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL4123129 | 0.85 | KDR (0.59) | MAPTRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL4105188 | 0.85 | MEN1 (0.59) | MAPTRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL1204773 | 0.85 | TP53 (0.66) | MAPTRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL4122745 | 0.85 | EPHX2 (0.66) | MAPTRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL4121995 | 0.85 | SAE1 (0.78) | MAPTRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL4105758 | 0.84 | KMT2A (0.65) | MAPTRAB9ASMN1; SMN2NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | MAPT 1654/4885RAB9A 815/4885SMN1; SMN2 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.